Vanda Pharmaceuticals Inc. last reported quarterly results on Oct 28, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $69.8 million (+24.1% year over year) and diluted EPS of -$0.37. It usually reports 28–42 days after a quarter ends. Based on that pattern, the next release is estimated for around Feb 10, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Wednesday. Based on last year's release for the same quarter on Feb 11, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 28–42 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Oct 28, 2026
28 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
70
+24.1%
|
-23
+0.1%
|
-0.37
+2.6%
|
|
Aug 5, 2026
36 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
51
-3.9%
|
-63
-129.8%
|
-1.04
-126.1%
|
|
May 6, 2026
36 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
52
+3.4%
|
-49
-64.7%
|
-0.82
-64.0%
|
|
Feb 11, 2026
42 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
57
+7.6%
|
-141
-2774.3%
|
-2.39
-2735.9%
|
|
Oct 29, 2025
29 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
56
+18.1%
|
-23
-324.2%
|
-0.38
-322.2%
|
|
Jul 31, 2025
31 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
53
+4.2%
|
-27
-502.2%
|
-0.46
-475.0%
|
|
May 7, 2025
37 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
50
+5.4%
|
-29
-611.4%
|
-0.50
-614.3%
|
|
Feb 13, 2025
44 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
53
+17.5%
|
-5
-104.7%
|
-0.08
-102.5%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- VNDA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Washington, DC
- SEC filer status
- Accelerated filer
- SEC CIK
- 1347178
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.